+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Gene Therapy for CNS Disorders Market 2019-2023 - Product Image

Global Gene Therapy for CNS Disorders Market 2019-2023

  • ID: 4764932
  • Report
  • March 2019
  • Region: Global
  • 119 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Biogen
  • bluebird bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Voyager Therapeutics
  • MORE
The increase in special drug designations is one of the key factors anticipated to witness continuous growth in the forthcoming years. Vendors are receiving special drug designations for their novel gene therapies to help in receiving quicker approval. Some market players are even offering the orphan drug designation with various tax benefits on their clinical researches. As a result, the rising number of special drug designations from the regulatory bodies will drive the gene therapy for CNS disorders market growth in the forthcoming years. The analysts have predicted that the gene therapy for CNS disorders market will register a CAGR of nearly 27% by 2023.

Market Overview

Increase in special drug designations

One of the growth drivers of the global gene therapy for CNS disorders market is the increase in special drug designations. The increasing number of special drug designations from the regulatory bodies is expected to result in the quicker approval of gene therapy programs, which drives the growth of the market.

Uneven distribution of technology

One of the challenges in the growth of the global gene therapy for CNS disorders market is the Uneven distribution of technology. The lack of focus of major vendors on developing gene therapy for CNS disorders are expected to hinder the market growth during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the gene therapy for CNS disorders market during 2019-2023, view this report.

Competitive Landscape

The market appears to be highly concentrated with the presence of a few market players. Vendors in the market are developing advanced technologies that help in manufacturing gene therapies with superior efficacy for the treatment of various CNS indications. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biogen
  • bluebird bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Voyager Therapeutics
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY INDICATION
  • Market segmentation by indication
  • Comparison by indication
  • SMA - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by indication
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Biogen
  • bluebird bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Voyager Therapeutics
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global gene therapy for CNS disorders market pipeline: Overview
Exhibit 18: Global gene therapy for CNS disorders market pipeline: Snapshot
Exhibit 19: Indication - Market share 2018-2023 (%)
Exhibit 20: Comparison by indication
Exhibit 21: SMA - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: SMA - Year-over-year growth 2019-2023 (%)
Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by indication
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Biogen - Vendor overview
Exhibit 50: Biogen - Business segments
Exhibit 51: Biogen - Organizational developments
Exhibit 52: Biogen - Geographic focus
Exhibit 53: Biogen - Key offerings
Exhibit 54: Biogen - Key customers
Exhibit 55: bluebird bio, Inc. - Vendor overview
Exhibit 56: bluebird bio, Inc. - Product segments
Exhibit 57: bluebird bio, Inc. - Organizational developments
Exhibit 58: bluebird bio, Inc. - Key offerings
Exhibit 59: bluebird bio, Inc. - Key customers
Exhibit 60: Novartis AG - Vendor overview
Exhibit 61: Novartis AG - Business segments
Exhibit 62: Novartis AG - Organizational developments
Exhibit 63: Novartis AG - Geographic focus
Exhibit 64: Novartis AG - Segment focus
Exhibit 65: Novartis AG - Key offerings
Exhibit 66: Novartis AG - Key customers
Exhibit 67: Pfizer Inc. - Vendor overview
Exhibit 68: Pfizer Inc. - Business segments
Exhibit 69: Pfizer Inc. - Organizational developments
Exhibit 70: Pfizer Inc. - Geographic focus
Exhibit 71: Pfizer Inc. - Segment focus
Exhibit 72: Pfizer Inc. - Key offerings
Exhibit 73: Pfizer Inc. - Key customers
Exhibit 74: Voyager Therapeutics - Vendor overview
Exhibit 75: Voyager Therapeutics - Business segments
Exhibit 76: Voyager Therapeutics - Organizational developments
Exhibit 77: Voyager Therapeutics - Key offerings
Exhibit 78: Voyager Therapeutics - Key customers
Exhibit 79: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Biogen
  • bluebird bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Voyager Therapeutics
  • MORE
Global Gene Therapy for CNS Disorders Market 2019-2023

The analyst recognizes the following companies as the key players in the global gene therapy for CNS disorders market: Biogen, bluebird bio, Inc., Novartis AG, Pfizer Inc., and Voyager Therapeutics.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the changing perception related to ethical issues.”

According to the report, one of the major drivers for this market is the advent of novel technologies.

Further, the report states that one of the major factors hindering the growth of this market is the uneven distribution of technology.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Biogen
  • bluebird bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Voyager Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll